Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004053716 | SCV002647478 | uncertain significance | not specified | 2022-06-15 | criteria provided, single submitter | clinical testing | The p.N190S variant (also known as c.569A>G), located in coding exon 1 of the PALLD gene, results from an A to G substitution at nucleotide position 569. The asparagine at codon 190 is replaced by serine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005025803 | SCV005657684 | uncertain significance | Pancreatic cancer, susceptibility to, 1 | 2024-01-23 | criteria provided, single submitter | clinical testing |